Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: Mike Relyea who wrote (1487)	6/15/1998 9:44:00 AM
From: jad	Respond to of 1693

I liked the statement the new CEO made regarding planned growth: Double Digit revenue growth Earnings growth twice that of revenue growth Annual 5 year growth twice that of the diagnostic market Now, can he deliver - and how long do we have to wait to see a reflection on the stock price? Joe

To: Mike Relyea who wrote (1487)	6/16/1998 2:02:00 AM
From: Mr. Sunshine	Respond to of 1693

Mike, Thanks for the review of the conference call. I was not able to listen to it directly, so your informed comments were extremely welcome! Go QDEL!!! Good investing to all, Steve

To: Mike Relyea who wrote (1487)	6/17/1998 8:50:00 PM
From: Mark C. Livermore	Respond to of 1693

Mr.DeBruin came from Somatogen where from August of 1994 to it's being sold to Baxter in 1998 generated only a 3% compound rate of return to investors. That's right 3%. Note that at SMTG he owned virtually no stock only a ton of options-He participates in any upside but has none of his own money at risk. The fact that at another company he's been hired by with the same deal is very troubling. I hope that the results in QDEL do not mirror SMTG. P.S. He was only making 350k at SMTG.